Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C] BMS-986278, BMS-986278 Tablet, Admilparant
BMS-986278 · 7 trials · 8 indications
Cohort 1
Cohort 2
Percent predicted forced vital capacity (ppFVC) is the percentage of predicted value per participant of forced vital capacity (FVC). FVC is defined as the maximum capacity of air that a participant can exhale after a maximum inspiration as measured by the volume of air exhaled in a spirometer. The data is reported as percent change from baseline in ppFVC. Percent change from baseline is a calculation that expresses the change in a value compared to its initial starting point (baseline) as a percentage, showing how much a value has increased or decreased relative to its original level; it's calculated by subtracting the baseline value from the new value, dividing by the baseline value, and then multiplying by 100%. The percent change in this endpoint was calculated from ppFVC values taken at baseline, which is defined as the measurement of ppFVC taken at first dose, and ppFVC values taken at Week 26. This endpoint reports data for the IPF cohort only as pre-specified in the protocol.
| Arm | Type | Description |
|---|---|---|
| BMS-986278 Arm | EXPERIMENTAL | - |
| BMS-986278 Dose 1 | EXPERIMENTAL | - |
| BMS-986278 Dose 2 | EXPERIMENTAL | - |
| BMS-986278 Placebo | PLACEBO_COMPARATOR | - |
| IPF Dose 1 + Post Treatment Follow-up or OTE | EXPERIMENTAL | IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension) |
| IPF Dose 2 + Post Treatment Follow-up or OTE | EXPERIMENTAL | - |
| IPF Placebo + Post Treatment Follow-up or OTE | PLACEBO_COMPARATOR | - |
| PF-ILD Dose 1 + Post Treatment Follow-up or OTE | EXPERIMENTAL | PF-ILD (Progressive Fibrotic Interstitial Lung Disease) |
| PF-ILD Dose 2 + Post Treatment Follow-up or OTE | EXPERIMENTAL | - |
| PF-ILD Placebo + Post Treatment Follow-up or OTE | PLACEBO_COMPARATOR | - |
| Part 1: Treatment A | EXPERIMENTAL | - |
| Part 1: Treatment B | EXPERIMENTAL | - |
| Part 2: Treatment C | EXPERIMENTAL | - |
| Part 2: Treatment D | EXPERIMENTAL | - |
| Group A and C | EXPERIMENTAL | - |
| Group B: Period 1 | EXPERIMENTAL | - |
| Group B: Period 2 | EXPERIMENTAL | - |
| BMS-986278 | EXPERIMENTAL | - |
| Pirfenidone | EXPERIMENTAL | - |
| BMS-986278 + Pirfenidone | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986278 | DRUG | Specified dose on specified days |
| BMS-986278 Placebo | DRUG | Specified dose on specified days |
| Admilparant | DRUG | Specified dose on specified days |
| Pirfenidone | DRUG | capsule |
Inclusion Criteria: \- Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015. Exclusion Criteria: * Any disease/condition that, in the investigator's judgment, may pose ...
Top 15 of 17 competitors
BMS-986278 is an investigational oral small molecule developed by Bristol-Myers Squibb for pulmonary fibrosis. It is being studied in Phase 3 clinical trials for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, and it has also been evaluated in a Phase 1 study in people with severe renal impairment or end-stage renal disease on intermittent hemodialysis.
BMS-986278 targets LPA1, the lysophosphatidic acid receptor 1, a G protein-coupled receptor. By acting on this receptor, the small molecule is designed to interfere with LPA1 signaling, a pathway implicated in fibrosis. LPA1 antagonism is the mechanism under study in the pulmonary fibrosis programs.
BMS-986278 is being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, both chronic lung conditions marked by scarring of lung tissue. It is investigational and has not been established as a treatment. A separate Phase 1 study examined the drug in chronic kidney failure, including severe renal impairment and end-stage renal disease.
Bristol-Myers Squibb Company (ticker BMY) is the developer of BMS-986278. The company sponsors the Phase 3 pulmonary fibrosis trials and the completed Phase 1 renal impairment study of the compound.
BMS-986278 is in Phase 3 development. Two Phase 3 trials are underway in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, both currently active and not recruiting, and a Phase 3 long-term extension study in pulmonary fibrosis is not yet recruiting. A Phase 1 renal impairment study has been completed.
BMS-986278 trials include NCT06003426 in idiopathic pulmonary fibrosis, NCT06025578 in progressive pulmonary fibrosis, and the long-term extension NCT07441408 in pulmonary fibrosis, all Phase 3. The completed Phase 1 study NCT06723535 evaluated the drug in normal renal function, severe renal impairment, and end-stage renal disease on hemodialysis.
Yes, admilparant is another name for BMS-986278. The compound is also written as BMS 986278, and study materials refer to the BMS-986278 tablet and to [14C] BMS-986278, the radiolabeled form used in drug disposition research. All of these names refer to the same LPA1-targeting small molecule from Bristol-Myers Squibb.